A systematic review with separate Bayesian random-effects network meta-analyses compared the efficacy (treatment success) and safety (treatment-emergent adverse events) of pharmacological regimens for MAC pulmonary disease (MAC-PD) and MAC bacteremia in adults, drawing on 26 studies (16 RCTs, 10 cohort studies; n=3,574) published up to August 2026.
For MAC-PD, ALIS added to guideline-based therapy (ALIS_GBT) ranked highest for efficacy (SUCRA=0.974; OR 5.74, 95% CrI 3.45–9.87 vs. GBT alone) but also carried the highest TEAE risk (OR 3.62, 95% CrI 1.63–8.77 vs. GBT). For MAC bacteremia, GBT alone ranked highest for treatment success (SUCRA=0.849), while clofazimine-containing regimens were associated with significantly lower odds of success (clofazimine + rifamycin/ethambutol/fluoroquinolone: OR 0.18, 95% CrI 0.09–0.33; clofazimine + macrolide: OR 0.52, 95% CrI 0.27–0.97).
Substantial heterogeneity was observed for treatment success outcomes in both disease networks; evidence was sparse for several comparisons; safety reporting was variable across studies; and transitivity assumptions may not fully hold given differences in patient populations and disease manifestations across studies.
ALIS added to guideline-based therapy is a potent but adverse-event-prone option best reserved for refractory or difficult-to-treat MAC pulmonary disease. In MAC bacteremia, clinicians should favor standard guideline-based therapy over clofazimine-containing regimens, which showed meaningfully worse treatment success in this analysis.
Explore related topics